Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose study of JNJ-55363932 in healthy adults
NL-OMON51472Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing JNJ-55363932 with Placebo (2 arms). Primary endpoints: Safety and tolerability, Pharmacokinetics in plasma and 2 more. Started Mar 2022; status: completed.
02
Drugs
JNJ-55363932
Beyond the preview
Go deeper on NL-OMON51472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51472.